what is INVOKANA®?

INVOKANA®—the longest-prescribed SGLT2 inhibitor in the US—is a once-daily pill that, used along with diet and exercise, has been proven to significantly lower blood sugar (A1C) and is the only type 2 diabetes pill approved to reduce the risk of 3 major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

The 2018 ADA guidelines state that INVOKANA® may be considered to reduce major CV events after lifestyle management and metformin in patients with T2D and established cardiovascular disease.

lower A1C

In most clinical studies, INVOKANA® 300 mg helped a majority of people reach the ADA-recommended A1C goal of less than 7%

  • significant A1C reduction

in adults with t2d and established cardiovascular disease

now approved by the FDA to

lower cardiovascular risk

INVOKANA® is the only type 2 diabetes pill approved to lower your risk of major cardiovascular events including:

  • heart attack
  • stroke
  • cardiovascular death

INVOKANA® is not for weight loss, but may help you lose weight—on average 2–3%

Results may vary by dose and when used alone or with certain other diabetes medications.

although it’s not a blood pressure medicine, you may see lower systolic blood pressure with INVOKANA®—on average 3–5 mmHg

Results may vary by dose and when used alone or with metformin, sitagliptin, or insulin.

the safety and efficacy of INVOKANA® has been demonstrated in more than 18,000 patients across 15 completed clinical trials

the most common side effects of INVOKANA® include genital yeast infections, urinary tract infections, and changes in urination


get the facts and start a great INVOKANA® conversation with your doctor, using this handy guide


now that you know the facts, see if you can save:

Janssen wants to help you explore cost support options for INVOKANA®

explore savings options